Tilarginine
- Generic Name
- Tilarginine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C7H16N4O2
- CAS Number
- 17035-90-4
- Unique Ingredient Identifier
- 27JT06E6GR
- Background
Tilarginine has been investigated for the basic science, treatment, and diagnostic of Obesity, Type 2 Diabetes, Ocular Physiology, and Regional Blood Flow.
- Associated Conditions
- -
- Associated Therapies
- -
Insulin and Sarcopenia in the Elderly
- Conditions
- Interventions
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2016-12-12
- Target Recruit Count
- 88
- Registration Number
- NCT00690534
- Locations
- ๐บ๐ธ
Sealy Center on Aging, University of Texas Medical Branch, Galveston, Texas, United States
Niacin to Improve Blood Flow in People With Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2007-07-30
- Last Posted Date
- 2020-09-10
- Target Recruit Count
- 30
- Registration Number
- NCT00508989
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
๐บ๐ธHoward University Hospital, Washington, District of Columbia, United States
Mechanisms of Choroidal Blood Flow Changes During Dark/Light Transitions
- Conditions
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2007-02-05
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 42
- Registration Number
- NCT00431392
- Locations
- ๐ฆ๐น
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
Sildenafil to Treat HIV-Associated Pulmonary Hypertension
- Conditions
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2019-12-17
- Target Recruit Count
- 20
- Registration Number
- NCT00327080
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Blockade of Vascular Potassium Channels During Human Endotoxemia
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2008-10-17
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 36
- Registration Number
- NCT00185003
Nitric Oxide and the Autonomic Nervous System
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 112
- Registration Number
- NCT00178919
- Locations
- ๐บ๐ธ
Autonomic Dysfunction Center, Nashville, Tennessee, United States
Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease
- Conditions
- First Posted Date
- 2004-11-05
- Last Posted Date
- 2019-11-05
- Target Recruit Count
- 18
- Registration Number
- NCT00095472
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
The Effect of Lopinavir/Ritonavir on Endothelial Function
- Conditions
- First Posted Date
- 2004-01-22
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 30
- Registration Number
- NCT00076414
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center (CC), Bethesda, Maryland, United States
Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease
- Conditions
- First Posted Date
- 2003-11-11
- Last Posted Date
- 2019-12-12
- Target Recruit Count
- 44
- Registration Number
- NCT00072826
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Nitric Oxide to Improve Blood Flow in Sickle Cell Disease
- Conditions
- First Posted Date
- 2001-02-02
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 65
- Registration Number
- NCT00009581
- Locations
- ๐บ๐ธ
Warren G. Magnuson Clinical Center (CC), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.